Salah G. Aoun

Salah G. Aoun

Auto-generated profile, based on publicly available information

Salah G. Aoun

Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
CBCarlos Bagley
Carlos Bagley
MMMatthew MacAllister
Matthew MacAllister
LDLuke Dosselman
Luke Dosselman
JMJessica Moreno
Jessica Moreno
SASalah G Aoun
Salah G Aoun
TATarek Y El Ahmadieh
Tarek Y El Ahmadieh
Lumbar spinal stenosis is a degenerative process that is extremely frequent in today’s aging population. It can result in impingement on the nerves of the cauda equina or on the thecal sac itself, and lead to debilitating symptoms such as severe leg pain, or restriction in the perimeter of ambulation, both resulting in dependency in daily activities. The impact of the disease is global and includes financial repercussions because of its involvement in the active work force group. Risk factors for the disease include some comorbidities such as obesity or smoking, daily habits such as an active lifestyle, but also genetic factors that are not completely elucidated yet. The diagnosis of lumbar stenosis can be difficult, and involves a combination of radiological and clinical findings. Treatment ranges from conservative measures with physical therapy and core strengthening, to steroid injections in the facet joints or epidural space, to a more radical solution with surgical decompression. The evidence available in the literature regarding the causes, diagnosis and treatment of lumbar spine stenosis can be confusing, as no level I recommendations can be provided yet based on current data. The aim of this manuscript is to provide a comprehensive and updated summary to the reader addressing the multiple aspects of this disease.

1 February 2020 in Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
EWEva M. Wu
Eva M. Wu
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh
CMCameron M. McDougall
Cameron M. McDougall
SASalah G. Aoun
Salah G. Aoun
NMNikhil Mehta
Nikhil Mehta
BWBabu G. Welch
Babu G. Welch
OBJECTIVE: Endovascular embolization has been established as an adjuvant treatment strategy for brain arteriovenous malformations (AVMs). A growing body of literature has discussed curative embolization for select lesions. The transition of endovascular embolization from an adjunctive to a definitive treatment modality remains controversial. Here, the authors reviewed the literature to assess the lesional characteristics, technical factors, and angiographic and clinical outcomes of endovascular embolization of AVMs with intent to cure.METHODS: Electronic databases—Ovid MEDLINE, Ovid Embase, and PubMed—were searched for studies in which there was evidence of AVMs treated using endovascular embolization with intent to cure. The primary outcomes of interest were angiographic obliteration immediately postembolization and at follow-up. The secondary outcomes of interest were complication rates. Descriptive statistics were used to calculate rates and means.RESULTS: Fifteen studies with 597 patients and 598 AVMs treated with intent-to-cure embolization were included in this analysis. Thirty-four percent of AVMs were Spetzler-Martin grade III. Complete obliteration immediately postembolization was reported in 58.3% of AVMs that had complete treatment and in 45.8% of AVMs in the entire patient cohort. The overall clinical complication rate was 24.1%. The most common complication was hemorrhage, occurring in 9.7% of patients. Procedure-related mortality was 1.5%.CONCLUSIONS: While endovascular embolization with intent to cure can be an option for select AVMs, the reported complication rates appear to be increased compared with those in studies in which adjunctive embolization was the goal. Given the high complication rate related to a primary embolization approach, the risks and benefits of such a treatment strategy should be discussed among a multidisciplinary team. Curative embolization of AVMs should be considered an unanticipated benefit of such therapy rather than a goal.

1 November 2013 in World Neurosurgery
Verified
Journal Article
Closed access
AGAruna Ganju
Aruna Ganju
SASalah G. Aoun
Salah G. Aoun
MDMarc R. Daou
Marc R. Daou
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh
ACAlice Chang
Alice Chang
BBBernard R. Bendok
Bernard R. Bendok

1 November 2013 in World Neurosurgery
Verified
Journal Article
Closed access
SASalah G. Aoun
Salah G. Aoun
BBBernard R. Bendok
Bernard R. Bendok
RRRudy J. Rahme
Rudy J. Rahme
RDRalph G. Dacey
Ralph G. Dacey
HBH. Hunt Batjer
H. Hunt Batjer

1 October 2016 in Stroke
Verified
Journal Article
Closed access
HAHadie Adams
Hadie Adams
VBVin Shen Ban
Vin Shen Ban
VLVille Leinonen
Ville Leinonen
SASalah G. Aoun
Salah G. Aoun
JHJukka Huttunen
Jukka Huttunen
THTerhi J. Huttunen
Terhi J. Huttunen
Background and Purpose—: Shunt dependent hydrocephalus after aneurysmal subarachnoid hemorrhage (aSAH) is a common sequela that may lead to poor neurological outcome and predisposes to various interventions, admissions, and complications. We reviewed post-aSAH shunt dependency in a population-based sample and tested the feasibility of a clinical risk score to identify subgroups of aSAH patients with increasing risk of shunting for hydrocephalus. Methods—: A total of 1533 aSAH patients from the population-based Eastern Finland Saccular Intracranial Aneurysm Database (Kuopio, Finland) were used in a recursive partitioning analysis to identify risk factors for shunting after aSAH. The risk model was built and internally validated in random split cohorts. External validation was conducted on 946 aSAH patients from the Southwestern Tertiary Aneurysm Registry (Dallas, TX) and tested using receiver-operating characteristic curves. Results—: Of all patients alive ≥14 days, 17.7% required permanent cerebrospinal fluid diversion. The recursive partitioning analysis defined 6 groups with successively increased risk for shunting. These groups also successively risk stratified functional outcome at 12 months, shunt complications, and time-to-shunt rates. The area under the curve–receiver-operating characteristic curve for the exploratory sample and internal validation sample was 0.82 and 0.78, respectively, with an external validation of 0.68. Conclusions—: Shunt dependency after aSAH is associated with higher morbidity and mortality, and prediction modeling of shunt dependency is feasible with clinically useful yields. It is important to identify and understand the factors that increase risk for shunting and to eliminate or mitigate the reversible factors. The aSAH-PARAS Consortium (Aneurysmal Subarachnoid Hemorrhage Patients’ Risk Assessment for Shunting) has been initiated to pool the collective insights and resources to address key questions in post-aSAH shunt dependency to inform future aSAH treatment guidelines.

1 June 2011 in Neurosurgical Focus
Verified
Journal Article
Closed access
DWDavid G. Weinberg
David G. Weinberg
OAOmar M. Arnaout
Omar M. Arnaout
RRRudy J. Rahme
Rudy J. Rahme
SASalah G. Aoun
Salah G. Aoun
HBH. Hunt Batjer
H. Hunt Batjer
BBBernard R. Bendok
Bernard R. Bendok
Object: Moyamoya disease (MMD) is a rare cerebrovascular disorder involving stenosis of the major vessels of the circle of Willis and proximal portions of its principal branches. Despite concerted investigation, the pathophysiology of the disorder has not been fully elucidated. Currently, the major proteins believed to play an active role in the pathogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), transforming growth factor–β 1 (TGFβ 1 ), and granulocyte colony-stimulating factor (G-CSF). In terms of the genetics, recent literature suggests a low penetrance autosomal dominant or polygenic mode of transmission involving chromosomes 3, 6, 8, 12, and 17 for familial MMD. This review summarizes the current knowledge on the histopathology, pathophysiology and genetics of MMD. Methods: A PubMed/Medline systematic study of the literature was performed, from which 45 articles regarding MMD pathophysiology were identified and analyzed. Conclusions: Moyamoya disease is characterized by the intimal thickening and media attenuation of the proximal vessels of the circle of Willis as well as the development of an aberrant distal vascular network. The primary proteins that are currently implicated in the pathophysiology of MMD include VEGF, bFGF, HGF, TGFβ 1 , and G-CSF. Furthermore, the current literature on familial MMD has pointed to a low penetrance autosomal dominant or polygenic mode of transmittance at loci on chromosomes 3, 6, 8, 12, and 17.